Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Oza, Amit M, Cook, Adrian D, Pfisterer, Jacobus, Embleton, Andrew, Ledermann, Jonathan A, Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S, Beale, Philip, Cervantes, Andrés, Park-Simon, Tjoung-Won, Rustin, Gordon, Joly, Florence, Mirza, Mansoor R, Plante, Marie, Quinn, Michael, Poveda, Andrés, Jayson, Gordon C, Stark, Dan, Swart, Ann Marie, Farrelly, Laura, Kaplan, Richard, Parmar, Mahesh K B, Perren, Timothy J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648090/
https://www.ncbi.nlm.nih.gov/pubmed/26115797
http://dx.doi.org/10.1016/S1470-2045(15)00086-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648090/
https://www.ncbi.nlm.nih.gov/pubmed/26115797
http://dx.doi.org/10.1016/S1470-2045(15)00086-8

Ejemplares similares